Artificial Intelligence2 years ago
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa
Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor...